Recently in Patent Litigation Category
The Supreme Court of the United States is scheduled to hear arguments regarding Prometheus v. Mayo on December 7, 2011. This case provides the Supreme Court the oppurtunity to clarify the Bilski ruling regarding patentable subject matter in light of the recent patent reform. In order to refresh your memory, we have provided a summary of the case thus far:
In Prometheus, the patent at issue is a method for administering and subsequently determining the level of toxicity caused by thiopurine drugs used to treat gastrointestinal and autoimmune diseases, including 6-mercaptopurine ("6-MP") and azathiopurine ("AZA"). The latter is merely a "pro-drug" that converts to 6-MP upon administration to a patient. Prior to filing these claims, these drugs had been widely used to treat diseases such as inflammatory bowel disease and Crohn's disease, but had sometimes caused complications with non-responsiveness and drug toxicity. As such, the claimed method is a two-step method for (a) "administering" the drug, and (b) "determining" the levels of the drugs metabolites in order provide the doctor with instructions for the next dosage.
The Federal Circuit has decided this case twice, most recently reviewing the case on remand in light of the Supreme Court's decision in Bilski. Upon hearing the case in the first instance, the Federal Circuit overturned the district court's finding that Prometheus's asserted medical treatment method was drawn to non-patentable subject matter under §101. In making this finding, the Federal Circuit applied the machine-or-transformation test, and found the process to be transformative. However, after the Federal Circuit handed down this ruling, the Supreme Court handed down the famous (or infamous?) Bilski ruling which rendered the machine-or-transformation test "a useful and important clue" of patent eligibility under §101, instead of the sole test. Due to this, the Federal Circuit's initial ruling was vacated, and the case was remanded to be reconsidered in light of the Supreme Court's Bilksi determination.
Upon remand, the court once again found the claimed method to be drawn to patentable subject matter. However, this time the Federal Circuit provided alternate, but similar, reasoning. In addition to only examining the claimed method under the machine-or-transformation test for a clue as to the patentability of the method, the Court also analyzed whether the method was merely claiming an abstract idea.
For more information regarding the Federal Circuit's Ruling upon remand, please continue reading.
Many opponents of PGR believe this system will make it harder to acquire patents and will deter, instead of spur, innovation. However, post grant review, if implemented properly, can provide cheaper alternatives to businesses looking to secure solid intellectual property rights, as documented in a 2006 study arguing for the introduction of a post grant review system. Instead of acquiring a patent and fending off multiple law suits, PGR can provide a cheaper and faster alternative to litigation. While PGR may increase some start up costs associated with contested intellectual property, it may decrease costs in the long run so long as the costs associated with PGR remain low.
For more information about the PGR system, please keep reading.
CAFC Affirms Rejection of Means-Plus-Function Claims On Different Grounds Than the PTO: In re Aoyama
Yesterday the Federal Circuit issued In re Aoyama, in which a three-judge panel of Judge Newman, Judge Gajarsa, and Judge Linn affirmed the rejection of two claims which had been rejected as anticipated. Judge Newman dissented. The court, however, affirmed the Board of Patent Appeals and Interferences' (the Board) rejection under new grounds, finding no permissible construction of the claims, and thus, holding the two claims in question indefinite under §112 ¶2.
This ruling has the effect of broadening the court's options when reviewing decisions of the Board. Further, this case has precedential value in defining definiteness. However, the Court constructed the opinion fairly narrowly, drawing any conclusions back to the specifics of the case and the means-plus-functions claims at issue. Thus, it seems the precedential value of this opinion may be limited to cases involving computer implemented means-plus-functions claims.
For more details on the court's ruling, please keep reading.
In the latest episode of software giant patent infringement lawsuits, Microsoft has sued Motorola over non-US made handheld phones. Microsoft alleges that various Motorola phones, including the Droid 2, Droid X and Backflip, infringe seven of Microsoft's patents. The patents in question relate to the android mobile operating system and involve methods for, among others, ActiveSync email synchronization patents.
Considering that Google is set to acquire Motorola, this suit is the latest suit in the web of suits between Apple, Microsoft, Google, and other tech companies. (Click here for a good graphic documenting these suits) Based on the rash of litigation surrounding Android software, it appears that any company attempting to manufacture or sell android software is going to be involved in litigation. However, Microsoft has already won a case against HTC and is currently receiving $5.00 per phone. Thus, it is perceived that this suit is merely a negotiating tool for a similar licensing structure. It is rumored that Microsoft is now looking for royalties between $7.00 and $12.00 per device.
Despite the outrage due to the large number of suits in the software patent arena, a majority of civil suits, regardless of the subject matter, are settled before they ever reach court. If one of these software suits is able to reach the Federal Circuit, the Federal Circuit may be able to set down firm precedent to prevent future lawsuits. Until then, however, these suits should not be reason for outrage, and can merely be viewed as negotiating chips, as they have yet to prove to be much more. Microsoft has a large patent portfolio, a valuable business asset, and is using this asset just as any other asset is used, to generate a profit.
Frequently Asked Questions
Authors
